Funeral ceremony for Tu-154 crash victims held at military memorial cemetery near MoscowSociety & Culture January 16, 14:57
Russian combat engineers defuse over 20,000 munitions in AleppoMilitary & Defense January 16, 14:41
Kremlin: Russia is not going to groundlessly accuse other countries of cyberattacksRussian Politics & Diplomacy January 16, 14:30
Russian Helicopters sign first contract for civil products supply to PakistanBusiness & Economy January 16, 14:25
Montenegro accuses Russian national of inciting assassination plot against ex-premierWorld January 16, 13:48
IAC commission to join investigation of Bishkek air crashWorld January 16, 13:38
Kudrin says pension age should be raised starting from 2019 in RussiaBusiness & Economy January 16, 13:32
Flight recorder recovered at crash site of cargo Boeing-747 near Bishkek — sourceWorld January 16, 13:28
Kremlin agrees with Trump that NATO is 'vestige of past'Russian Politics & Diplomacy January 16, 13:16
KHIMKI, September 6. (ITAR-TASS) – Russian scientists are currently working on the first ever vaccine which could help quit smoking; it may be available in pharmacies in as early as five years. Dmitry Ovchinnikov, Deputy Director General of the company developing the drug, Selecta RUS confirmed: “We’re currently going through the second phase of clinical trials.”
Selecta RUS is a subsidiary of an American innovation company which opened the Khimki branch in 2012. Ovchinnikov said that development of the ‘anti-tobacco’ and other vaccines was moved from the U.S. to Russia, as “experts of required qualification work here.” Favorable financing conditions were also a factor: for instance, the vaccine project has received a grant from Russia’s Ministry of Industry and Trade.
The scientists noted that “existing methods of curing tobacco addiction are ineffective,” adding that the new vaccine will be a breakthrough. The drug makes recipient’s body start producing antibodies which block nicotine before it reaches the brain.
Khimki lab scientists are working on a molecular “nano-container,” which can precisely deliver vaccine components in cells which are responsible for launching immune reaction. Produced anti-bodies bind nicotine contained in blood; the resulting complex becomes too large to bypass the blood–brain barrier, which restrict diffusion of dangerous microscopic objects, such as bacteria and harmful molecules. As a result, nicotine cannot access the brain’s “pleasure center” – thus smoking ceases to bring the feeling of euphoria and satisfaction. The chain of pathological tobacco addiction is thus broken.
Ovchinnikov added that Selecta RUS scientists are also working on other vaccines against other afflictions such as melanoma, type 1 diabetes and hepatitis B.
“Operation of this laboratory is a vivid example of technology transfer to Russia,” said Sergei Filippov, representative of Rusnano. He added that Rusnano owns 12% of SelectaBiosciences, the American company which owns Selecta RUS.